Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05583734 · ClinicalTrials.gov registry record · NA

A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy

A NA study of Hematologic Malignancy, sponsored by Aperture Medical Technology.

Recruiting
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT05583734 is a NA study of Hematologic Malignancy that is actively recruiting participants, run by Aperture Medical Technology. The registered enrollment target is 32 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05583734, a NA study of Hematologic Malignancy, is actively recruiting participants, sponsored by Aperture Medical Technology.

RECRUITING
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This is a self-controlled, prospective trial. The objective of this trial is to evaluate the efficacy and safety of the Portomar(TM) device for bone marrow biopsy.

Conditions Studied

Interventions

  • DEVICE Portomar(TM) Device

Study Locations (1)

Texas

  • MD Anderson - Houston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-11-22
Est. Completion 2025-10
Phase NA

Sponsor

Aperture Medical Technology

1 total trials

What the Registry Record Tells You About NCT05583734

The ClinicalTrials.gov registry entry for NCT05583734 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (86% lower). The listed sponsor is Aperture Medical Technology, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Portomar(TM) Device is the first listed.

NCT05583734 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05583734 about?

NCT05583734 is a clinical study titled "A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy". This is a self-controlled, prospective trial. The objective of this trial is to evaluate the efficacy and safety of the Portomar(TM) device for bone marrow biopsy.

What is the current status of trial NCT05583734?

This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2022-11-22. Estimated completion is 2025-10.

What conditions does trial NCT05583734 study?

This clinical trial studies the following conditions: Hematologic Malignancy.

What interventions are being tested in trial NCT05583734?

The interventions under investigation include: Portomar(TM) Device (DEVICE).

Who is sponsoring clinical trial NCT05583734?

This trial is sponsored by Aperture Medical Technology, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05583734 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.